Transactions
AcuraBio recapitalized by Ampersand Capital Partners
Aug. 2022
Client: AcuraBio is an Australia-based contract development and manufacturing organization (CDMO) that provides specialized drug development and biomanufacturing services to the pharmaceutical, biotechnology, and veterinary industries worldwide
Role: Edgemont Partners acted as financial advisor to AcuraBio for its recapitalization by Ampersand Capital Partners
Location: Brisbane, Australia
Sector: Pharmaceutical Services
Lead Banker: Andrew Karlin
recapitalized by
